you've been saying this same thing for two years now Joanie and yet the short numbers have reached their highest level ever. Me thinks you are here to deflect attention from the reality of the pathetic SP. and high short position. Something smells and management's complacently quiet.
Joko's been screaming how high it's become. They always cover. Question is how & when.
"It seems that Short Player because he may be well funded, is aware of the Clinical Trials. Lets face it, if the trials was going poorly would we have such a large short position." well the obvious answer is yes, hence our concerns.
Imet results were impressive for ET...over 90% response rate. It appears ET/PV trial maybe very well be the next indication announced or implied under label for Imet by Janssen
I was scared to answer earlier as Joko started speaking in tongues at tonight's Gerontology church choir meeting.
Honestly I can't see Jansen releasing preliminary data till they reach a continuum decision based on that data. Realistically with the first patient started infusing two weeks ago and 19 more patients will be required for this milestone decision my guess would be earlier next year before we know.
ASH 2015 however may shed a light on the MAYO trial data updates on ET/PV & AML underlying the decision to continue the former MAYO MF, AML & a wider MDS application.
To quote Gryaznov's interview earlier by Kanak;
actually it's specific to very few comparatively. #rd world countries will ot be able to afford it @ $120K / treatment. Perhaps India & China where they would/could produce it off patent but that wouldn't help our bottom line here Joko. Don't give me that humanitarian facade...you're capitalizing on pumping a stock to make daily gains on buys and sells.
are you sure you don't mean years? If it was months Jansen would have already applied for it. They haven't as yet. Won't happen until we get current Phase ll preliminary data results...only one infusion we know of and 6 sites recruiting. We need results from at least 20 patients for J&J confirmation of continuum and following that then perhaps fast tracked status will be sought.
yeah the only healthy male 63 year old in Russia is Putin, the rest are all dead by then. Russia has the lowest male life expectancy @ 64 placing it among the lowest 50 countries in the world in that category.
" no one has launched missles into Oil fields to prop up prices" ...whadyah call Iraq, Lybia and Syria?
As to Calgary based oil technology fracking has given N. America a new lease on domestic supply but at a much higher cost.
I'm sure those German engineers don't mind a mis-spell. A Porshe is a race car attaining break neck speeds, GERN is like my porch out front hodge podge lodge...something you sit on whilst watch the leaves turn color and fall & the pond levels go up and down till freeze up.
July 19, 2005
Biotech company Geron Corp. said Monday that it had signed a licensing deal with drug maker Merck & Co. to develop a cancer vaccine that targets an enzyme linked to tumor growth, sending Geron shares up 27%.
Under the terms of the agreement, Geron will receive an upfront payment, milestone payments upon achievement of certain development and regulatory events, and royalties. Specific terms were not disclosed.
Merck has a long history of making conventional vaccines, which prevent infection by viruses and bacteria. Cancer vaccines, by contrast, work by stimulating the immune system to attack tumor cells that are already present in the body.
The Geron vaccine targets telomerase, an enzyme that Geron said was active in most cancer cells and that allows them to grow and multiply over long periods.
"Telomerase is always found in tumor cells, so this is one of the most compelling targets against cancer," said Steve Brozak, an analyst with WBB Securities in Westfield, N.J.
Merck, which is based in Whitehouse Station, N.J., and is one of the largest U.S. drug makers, also agreed to buy equity in tiny Geron at a future date as part of Geron's next round of financing. Additional terms were not disclosed.
Merck also acquired the option to negotiate a separate deal for Geron's dendritic cell-based telomerase vaccine. That vaccine is already in early-stage human trials. Dendritic cells are immune-system cells responsible for detecting and attacking foreign matter.
Geron, which is based in Menlo Park, Calif., will receive a payment from Merck in consideration for the option. The structure and terms of an agreement for the dendritic cell vaccine will be negotiated should Merck exercise its rights under the option.
Shares of Geron closed up $2.29 at $10.89
LOOK AT THE SP STUPID!